

Internal atrial cardioversion in atrial fibrillation

Giuseppe Boriani, Mauro Biffi, Claudia Camanini, Ivan Corazza, Cristian Martignani, Romano Zannoli, Angelo Branzi

Cardiovascular Department, Institute of Cardiology, University of Bologna, Bologna, Italy

(Ital Heart J 2000; 1 (Suppl 3): S114-S116)

Address:

Dr. Giuseppe Boriani
*Istituto di Cardiologia
Università degli Studi
Via Massarenti, 9
40138 Bologna*

Electrical cardioversion is usually performed using the transthoracic technique with delivery of monophasic shocks at 200-360 J and the efficacy results are 61-94%^{1,2}. However as little as 4% of the current from an external shock effectively penetrates cardiac tissue, while the majority follows other pathways through the chest³.

Low-energy internal atrial cardioversion is a relatively new procedure for restoring sinus rhythm in different forms of atrial fibrillation (AF).

Internal atrial cardioversion was initially performed on patients who were resistant to external cardioversion⁴. This procedure can be performed by delivering biphasic shocks between transvenous catheters positioned within the cardiac chambers or great vessels (usually between catheters positioned in the right atrium and coronary sinus or between catheters positioned in the right atrium and left pulmonary artery). Delivery of shocks results in effective cardioversion at energies < 6-10 J and the procedure can be effective even when external cardioversion has failed⁴. Independent of the lead configuration, the efficacy for terminating AF is very high, 92-100% for spontaneous episodes of paroxysmal AF and 70-100% for chronic persistent AF, with relatively low-energy requirements, especially when dealing with paroxysmal AF^{2,4-8}.

Atrial defibrillation threshold is usually evaluated in clinical studies by adopting a step up protocol⁹⁻¹³ and this implies some approximation in comparison with the methodology used for defibrillation threshold evaluation in animal studies. Besides clinical issues (type of AF, AF duration, etc.), atrial

defibrillation threshold is also dependent upon electrode design and materials¹⁴, electrode size⁹, electrode coil length¹⁰, electrode position and shock configuration^{6,11-13}. Moreover, atrial defibrillation threshold is lower when biphasic versus monophasic shock waveforms are delivered¹⁵, when asymmetrical waveforms with the second phase shorter than the first phase are used¹⁵⁻¹⁷, and when sequential shocks are delivered through dual current pathways¹⁸.

Patient tolerability to shock delivery is variable and may be influenced by psychological status, patient conditioning, number of shocks delivered, energy delivered, shock waveform, and lead positioning^{5,8,16,19-23}. Shock-induced discomfort varies from patient to patient, but the procedure can be usually performed without general anesthesia under mild sedation if necessary. Nevertheless, tolerability has to be improved by obtaining substantial reduction in defibrillating thresholds.

We reported the feasibility of the procedure with no or mild sedation in a substantial proportion of patients^{8,24}. Improved tolerance was observed using rounded biphasic waveforms²⁵, asymmetrical waveforms¹⁷, and higher capacitance waveforms¹⁶. In addition, pharmacological interventions which reduce defibrillation thresholds may also reduce patient discomfort^{13,26}. In clinical practice, the lowest number of shocks to restore sinus rhythm is preferable²⁷.

The safety issue was obviously investigated because delivery of shocks for defibrillating the atria implies a potential risk of inducing ventricular fibrillation. In order to minimize the risk of inducing ventricular tachyarrhythmias, shock delivery must

be synchronous to the QRS and should be avoided during rapid RR cycles (< 300 ms)²⁸.

The risk of AF recurrence following internal cardioversion is related to atrial remodeling of electrophysiological properties and is particularly high in the first days after restoration to sinus rhythm, and appropriate pharmacological prevention of AF recurrence is required²⁹.

Although at present time transvenous low-energy cardioversion is still an investigational procedure, a broadening of its indications is expected in the near future. Indications for transvenous low-energy internal cardioversion for AF may be classified as follows:

accepted indications: AF with clinical indications for restoring sinus rhythm with failure of external cardioversion, AF occurring during electrophysiological study;

potential indications: AF in obese patients, AF in patients in whom avoidance of general anesthesia is indicated (elderly patients, patients with respiratory insufficiency, low cardiac output, and chronic obstructive pulmonary disease), AF in patients who refuse general anesthesia, AF in patients in whom sinus node dysfunction or sick sinus syndrome is highly suspected;

possible future indications: AF occurring in intensive care units, AF occurring post-cardiac surgery.

The cost of the procedure, which remains invasive and requires a brief hospital stay, must be balanced with the benefit of restoring sinus rhythm and the possibility of maintaining sinus rhythm in the medium-long term.

Experimental and clinical investigations of low-energy internal cardioversion have resulted in the development of devices for atrial defibrillation (implantable atrial defibrillators or dual defibrillators) whose clinical role and cost-benefit ratio is currently under evaluation^{19,20}.

References

1. Ewy GA. Optimal technique for electrical cardioversion of atrial fibrillation. *Circulation* 1992; 86: 1645-7.
2. Alt E, Ammer R, Schmitt C, et al. A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion. *Eur Heart J* 1997; 18: 1796-804.
3. Lerman BB, Deale OC. Relation between transcardiac and transthoracic current during defibrillation in humans. *Circ Res* 1990; 67: 1420-6.
4. Nathan AW, Bexton RS, Spurrell RA, Camm AJ. Internal low energy cardioversion for the treatment of cardiac arrhythmias. *Br Heart J* 1984; 52: 377-84.
5. Murgatroyd FD, Slade AKB, Sopher SM, Rowland E, Ward DE, Camm AJ. Efficacy and tolerability of transvenous low-energy cardioversion of paroxysmal atrial fibrillation in humans. *J Am Coll Cardiol* 1995; 25: 1347-53.
6. Levy S, Ricard P, Gueunoun M, et al. Low-energy cardioversion of spontaneous atrial fibrillation. Immediate and long-term results. *Circulation* 1997; 96: 253-9.
7. Levy S, Ricard P, Lau CP, et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. *J Am Coll Cardiol* 1997; 29: 750-5.
8. Boriani G, Biffi M, Bronzetti G, et al. Efficacy and tolerability in fully conscious patients of transvenous low-energy internal atrial cardioversion for atrial fibrillation. *Am J Cardiol* 1998; 81: 241-4.
9. Kalman JM, Power JM, Chen J, Farish SJ, Tonkin AM. Importance of electrode design, lead configuration and impedance for successful low energy transcatheter atrial defibrillation in dogs. *J Am Coll Cardiol* 1993; 22: 1199-206.
10. Boriani G, Biffi M, Sammal A, et al. Transvenous atrial cardioversion: a randomized comparison between catheters with different coil length. (abstr) *Pacing Clin Electrophysiol* 1999; 22: 850.
11. Alt E, Schmitt C, Ammer R, et al. Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation. *Am J Cardiol* 1997; 79: 621-5.
12. Lok NS, Lau CP, Tse HF, Ayers GM. Clinical shock tolerability and effect of different right atrial electrode locations on efficacy of low-energy human transvenous atrial defibrillation using an implantable lead system. *J Am Coll Cardiol* 1997; 30: 1324-30.
13. Krum D, Hare J, Mughai K, et al. Optimization of shocking lead configuration for transvenous atrial defibrillation. *J Cardiovasc Electrophysiol* 1998; 9: 998-1003.
14. Luceri RM, Accorti PR. Temporary transvenous cardioversion and defibrillation: a new method for practical tachyarrhythmia management. *Pacing Clin Electrophysiol* 1997; 20: 168-72.
15. Cooper RAS, Johnson EE, Wharton M. Internal atrial defibrillation in humans. Improved efficacy of biphasic waveforms and the importance of phase duration. *Circulation* 1997; 95: 1487-96.
16. Tomassoni G, Newby KH, Kearney MM, Brandon MJ, Barold H, Natale A. Testing different biphasic waveforms and capacitances: effect on atrial defibrillation threshold and pain perception. *J Am Coll Cardiol* 1996; 28: 695-9.
17. Boriani G, Biffi M, Zannoli R, Branzi A, Magnani B. Transvenous internal cardioversion for atrial fibrillation: a randomized study on defibrillation threshold and tolerability of asymmetrical compared with symmetrical shocks. *Int J Cardiol* 1999; 71: 63-9.
18. Cooper RAS, Plumb VJ, Epstein AE, Kay GN, Ideker RE. Marked reduction in internal atrial defibrillation thresholds with dual-current pathways and sequential shocks in humans. *Circulation* 1998; 97: 2527-35.
19. Heisel A, Jung J, Fries R, Schieffer H, Ozbek C. Atrial defibrillation: can modifications in current implantable cardioverter-defibrillators achieve this? *Am J Cardiol* 1996; 78 (Suppl 5A): 119A-127A.
20. Heisel A, Jung J. The atrial defibrillator: a stand-alone device or part of a combined dual-chamber system? *Am J Cardiol* 1999; 83 (Suppl D): 218D-226D.
21. Saksena S, Prakash A, Mangione L, et al. Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations. *Am J Cardiol* 1995; 76: 913-21.
22. Jung J, Heisel A, Fries R, Kollner V. Tolerability of internal low-energy shock strengths currently needed for endocardial atrial cardioversion. *Am J Cardiol* 1997; 80: 1489-90.
23. Santini M, Pandozi C, Gentilucci G, Villani M, Scianaro MC. Intra-atrial defibrillation of human atrial fibrillation. *J Cardiovasc Electrophysiol* 1998; 9: S170-S176.
24. Santini M, Pandozi C, Toscano S, et al. Changes in intracar-

- diac atrial cardioversion threshold at rest and during exercise. *J Am Coll Cardiol* 1997; 29: 576-81.
25. Harbinson MT, Allen JD, Imam Z, et al. Rounded biphasic waveform reduces energy requirements for transvenous catheter cardioversion of atrial fibrillation and flutter. *Pacing Clin Electrophysiol* 1997; 20: 226-9.
26. Boriani G, Biffi M, Capucci A, et al. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. *J Am Coll Cardiol* 1999; 33: 333-41.
27. Santini M, Pandozi C, Altamura G, et al. Single shock endocavitary low energy intracardiac atrial cardioversion of chronic atrial fibrillation. *J Interv Card Electrophysiol* 1999; 3: 45-51.
28. Ayers GM, Alferness CA, Ilina M, et al. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. *Circulation* 1994; 89: 413-22.
29. Boriani G, Biffi M, Zannoli R, Branzi A, Magnani B. Evaluation of atrial refractoriness and atrial fibrillation inducibility immediately after internal atrial cardioversion in patients with chronic persistent atrial fibrillation. *Cardiovasc Drugs Ther* 1999; 13: 507-11.